Article révisé par les pairs
Titre:
  • Neoadjuvant stereotactic body radiation therapy with durvalumab and oleclumab in ER+HER2- breast cancer: a randomized phase 2 trial.
Auteur:De Caluwé, Alex; Desmoulins, Isabelle; Cao, Kim-Anh Lê; Remouchamps, Vincent; Baten, Adinda; Longton, Eléonore; Peignaux, Karine; Joaquin Garcia, Andrea; Venet, David; Arecco, Luca; Agostinetto, Elisa; Nader-Marta, Guilherme; Denis, Zoe; Dhont, Jennifer; Kristanto, Paulus; Catteau, Xavier; Larsimont, Denis; Salgado, Roberto; Poortmans, Philip; Stagg, John; Sotiriou, Christos; Piccart, Martine; Ignatiadis, Michail; Romano, Emanuela; Buisseret, Laurence
Informations sur la publication:Nature medicine, 32, 7, page (2461-2472)
Statut de publication:Publié, 2026-07-01
Sujet CREF:Sciences bio-médicales et agricoles
MeSH keywords:Humans
Female
Neoadjuvant Therapy
Antibodies, Monoclonal -- administration & dosage -- therapeutic use -- adverse effects
Breast Neoplasms -- pathology -- genetics -- radiotherapy -- drug therapy -- therapy -- metabolism
Erb-b2 Receptor Tyrosine Kinases -- metabolism -- genetics
Middle Aged
Receptors, Estrogen -- metabolism -- genetics
Radiosurgery -- methods
Aged
Pathologic Complete Response
Adult
Tumor Microenvironment -- drug effects
Langue:Anglais
Identificateurs:urn:issn:1078-8956
info:doi/10.1038/s41591-026-04453-z
info:pii/10.1038/s41591-026-04453-z
info:pmid/42350643
PMC13375581

Documents en relation

DI-fusion